Feryskol AD Softgel Capsule is a scientifically advanced hematinic formulation engineered to combat and prevent complex nutritional deficiencies, particularly mixed anemia (Iron Deficiency Anemia and Megaloblastic Anemia) and associated peripheral neuropathy. Each softgel contains the highly bioavailable combination of Carbonyl Iron (50 mg) to rapidly replenish iron stores and maximize hemoglobin synthesis, and a therapeutic 5 mg dose of Folic Acid for optimal red blood cell production. The critical differentiator is the inclusion of Adenosylcobalamin (500 mcg), the active, coenzyme form of Vitamin B12, which is immediately ready for use by the body for nerve protection and cellular metabolism, making it superior to common inactive forms.
The demand for robust nutritional supplements in India is experiencing exponential growth, with the dedicated hematinic market segment expanding at an impressive 15% CAGR. This surge is driven by high rates of iron and B12 deficiencies across all demographics, particularly in pregnant women, the elderly, and those with poor dietary intake. The premium softgel presentation of Feryskol AD, combined with its high-potency, active ingredients, positions it as a highly sought-after product by doctors who require maximum efficacy for their patients. This makes the product an evergreen, recession-resistant asset with reliable, high-volume prescription potential for our B2B partners.
We invite you to capitalize on this enormous market opportunity by securing a PCD Pharma Franchise for Feryskol AD Softgel Capsule. Our franchise model provides comprehensive support, including strict monopoly rights in your chosen territory, ensuring you dominate the local market without competition. You will receive a full suite of marketing materials, including visual aids and product literature, alongside stock manufactured in our WHO-GMP certified facilities. Partnering with us for Feryskol AD guarantees access to a high-profit product line, backed by a commitment to quality and a strategic blueprint for rapid business growth in the fastest-growing therapeutic segment.